New treatment strategies for canine B-cell lymphoma are desperately needed. One promising target may be inhibition of the B-cell receptor (BCR) signaling pathway, which is commonly activated in dogs with high-grade B-cell lymphoma. Researchers will investigate the BCR signaling pathway's role in canine lymphoma cells and its potential as a therapeutic target. Information gained from this study may be useful in the development of a clinical trial to test new therapies in dogs with B-cell lymphoma.
Study ID
D15CA-026
Study Status
Complete
Start Date
01/01/2015
Grant amount awarded
$107,902
Grant recipient
The Ohio State University
Study country
United States
Investigator
William C. Kisseberth , DVM, PhD
Study category
Cancer